Education Shimla

HPU researcher develops enzyme-based method for tuberculosis drug intermediate

The process uses a fungal-derived enzyme to produce Rifamycin S, reducing the need for harmful chemicals in drug manufacturing.

Key points

  • HPU researcher Ekta Arya developed a method to produce Rifamycin S using a fungal-derived enzyme.
  • The process reduces the use of harmful chemicals in TB drug production and is suitable for industrial scale.
  • The research was presented at an international conference in Chennai and has been patented in India.

Researchers at Himachal Pradesh University (HPU) have developed a method to produce Rifamycin S, a key intermediate in tuberculosis drug manufacturing. The process uses a fungal-derived Rifamycin oxidase enzyme to convert Rifamycin B into Rifamycin S.

The research was conducted by Ekta Arya, a PhD student in the Biotechnology Department of HPU. The method aims to replace traditional chemical processes that use harmful chemicals, which may help reduce environmental pollution and production costs.

The process was tested at a one-liter scale. Using a free enzyme, the conversion was achieved in 15 minutes under conditions of 45 degrees Celsius and 200 rpm.

The study also compared the efficiency of free and immobilized enzymes. Using an immobilized enzyme, 1.76 mmol of product was obtained in 30 minutes.

High-performance liquid chromatography (HPLC) was used to analyse the product yield. The research suggests that this process is suitable for industrial-scale application.

The work was presented at an international conference in Chennai on innovations in medicine, public health, and life sciences. A patent for the research has been published by the Indian patent office.